Back to top

MTN-016 (EMBRACE) - Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure – A study that seeks to learn whether HIV prevention products containing ARVs can affect a woman’s pregnancy outcome or her baby’s general growth and development. The study involves the creation of a database of health information collected from women who unintentionally became pregnant while participating in an MTN trial, or who participated in MTN pregnancy or breastfeeding studies. Health information about their babies is also included.  More Info…

 

MTN-034 (REACH) - A Phase IIa trial that seeks to understand the HIV prevention needs and preferences of adolescent girls and young women, who are among those at highest risk of HIV in sub-Saharan Africa in a design that will evaluate both the monthly dapivirine ring and daily use of Truvada as oral pre-exposure prophylaxis (PrEP).  More info…

 

MTN-035 (DESIRE) - an open label crossover study to systematically examine multiple placebo methods for delivering drugs to help prevent HIV from anal sex.  More info…

 

MTN-038 - A Phase 1, Randomized, Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir.  More info…

 

MTN-039 - A Phase I study designed to evaluate the safety, acceptability and concentrations of drug in the rectal tissue of a fast-dissolving rectal insert containing the antiretroviral drugs tenofovir and elvitegravir. The study will include 20 men and women (cisgender or transgender) at two sites in the U.S.

 

MTN-042 (DELIVER) - A Phase IIIb open-label study being planned that will evaluate the dapivirine vaginal ring and Truvada as daily PrEP (pre-exposure prophylaxis) in pregnant women to determine whether use of these products is safe for both women and their infants. The study will be conducted at trial sites in Malawi, Uganda, South Africa and Zimbabwe. Of the 750 women who will be enrolled, 500 will use the vaginal ring. The study is the first to be conducted of the dapivirine ring during pregnancy.  More info...

 

MTN-043 (B-PROTECTED)  - A Phase IIIb open-label trial under development that will evaluate whether the dapivirine ring and Truvada as daily PrEP are safe to use by women who are breastfeeding. The study, which will be conducted at trial sites in Malawi, Uganda, South Africa and Zimbabwe, will enroll up to 200 mothers and their breastfed babies. The MTN has already conducted a study (MTN-029/IPM 039) that involved U.S. women who were no longer nursing their babies but still producing milk, which found dapivirine was absorbed at very low concentrations in breastmilk.  More info...

 

MTN-044/IPM 053/CCN019 - A Phase I study of a 90-day vaginal ring containing the antiretroviral dapivirine and the contraceptive hormone levonorgestrel to prevent both HIV and unintended pregnancy. The study, currently enrolling 24 women at one site in the U.S., will evaluate the safety and acceptability of the ring.

 

MTN-045 - A cross-sectional study using questionnaires and other measures to assess couples’ preferences for dual purpose prevention products to prevent unintended pregnancy and HIV infection. The study findings will inform the future design and delivery of products.